IPSC (Century Therapeutics) 10-Year Sortino Ratio: N/A (As of Sep. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IPSC Century Therapeutics Inc IPSC
46 GF Score
Price $2.08
GF Value $40.12
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Century Therapeutics 10-Year Sortino Ratio?

The 10-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past ten years. As of today (2026-09-08), Century Therapeutics's 10-Year Sortino Ratio is Not available.


Century Therapeutics  (NAS:IPSC) 10-Year Sortino Ratio Explanation

The 10-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past ten year. It is calculated as the annualized result of the average ten-year monthly excess returns divided by the standard deviation of negative returns in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.


Century Therapeutics 10-Year Sortino Ratio Related Terms


IPSC vs UPB, ZNTL, FHTX: 10-Year Sortino Ratio Comparison

For the Biotechnology subindustry, Century Therapeutics's 10-Year Sortino Ratio, along with its competitors' market caps and 10-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Century Therapeutics 10-Year Sortino Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Century Therapeutics's 10-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where Century Therapeutics's 10-Year Sortino Ratio falls into.


IPSC
46GF Score
Century Therapeutics Inc IPSC
10-Year Sortino Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Century Therapeutics 10-Year Sortino Ratio Calculation

The 10-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last ten year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 10-Year Sortino Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past ten year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.

Is Century Therapeutics (IPSC) Overvalued in 2026?

Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued. The current stock price of $2.08 is trading 94.8% below its estimated GF Value™ of $40.12. GuruFocus considers Century Therapeutics to be Possible Value Trap.

Key valuation signals for IPSC:

  • 10-Year Sortino Ratio: N/A
  • GF Value™: $40.12 vs. price of $2.08 (94.8% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Century Therapeutics Business Description

Address 25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score

Get the complete analysis for IPSC

10-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price
$40.12
GF Value